Khan J, Yap C, Clark R, Fenwick N, Marin D (2013): Practical implementation of an adaptive phase I/II design in chronic myeloid leukaemia: evaluating both efficacy and toxicity using the EffTox design. Trials 2013, 14(Suppl 1):P20
Earl, H.M. Vallier, A.L. Hiller, L. Fenwick, N. Young, J. Iddawela, M. Abraham, J. Hughes-Davies, L. Gounaris, I. McAdam, K. Houston, S. Hickish, T. Skene, S. Chan, S. Dean, S. Ritchie, D. Laing, R. Harries, M. Gallagher, C. Wishard, G. Dunn, J. Provenzano, E. Caldas, C. for the Neo-tAnGo Investigators. (2013), Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and aplictaxel for wmen with high-risk early breast cancer (Neo0tAnGo): an open-label, 2x2 factorial randomised phase 3 trial. Lancet Oncol 2013. Published online December 19, 2013. http://dx.doi.org/10.1016/S1470-2045(13)70554-0 and online comment http://dx.doi.org/10.1016/S1470-2045(13)70584-9
Provenzano, E. A-L Vallier, A.L. Champ, R. Walland, K. Bowden, S. Grier, A, Fenwick, N. Abraham, J. Iddawela, M. Caldas, C. Hiller, L. Dunn, J. Earl, H.M. (2013), A central review of histology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. British Journal of Cancer (2013) 108, 866–872. doi:10.1038/bjc.2012.547 www.bjcancer.com.
H. M. Earl, A. Vallier, L. Hiller, N. Fenwick, M. Iddawela, L. Hughes-Davies, E. Provenzano, K. McAdam, T. Hickish, C. Caldas, for NeotAnGo Investigators (2009), Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR), J Clin Oncol 27:15s, 2009 (suppl; abstr 522)